Literature DB >> 17894925

Treatment of chronic low back pain with botulinum neurotoxins.

Bahman Jabbari1.   

Abstract

In a double-blind, randomized, placebo-controlled study, administration of botulinum toxin A (Botox; Allergan Inc., Irvine, CA) into paraspinal muscles using a novel technique produced significant pain relief in 60% of patients with chronic, refractory low back pain. A similar yield of 53% was noted in a prospective, randomized, open-label study of 75 patients, with 14 months of follow-up. In this study, an early response predicted later responsiveness, with 91% of the responders continuing to respond to repeat injections. The technique of treatment for both studies included covering the whole length of the lumbar erector spinae with one injection given at each lumbar level regardless of pain, tenderness, or trigger point location(s). The dose per injection site was 50 U (Botox), with the total dose per session not to exceed 500 U. Side effects were uncommon and consisted of a transient, mild flu-like reaction in 5% of the patients. Botulinum treatment of paraspinal muscles can reduce pain in a substantial number of patients with refractory chronic low back pain and is safe in the recommended doses.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17894925     DOI: 10.1007/s11916-007-0217-1

Source DB:  PubMed          Journal:  Curr Pain Headache Rep        ISSN: 1534-3081


  24 in total

1.  Presynaptic effects of botulinum toxin type A on the neuronally evoked response of albino and pigmented rabbit iris sphincter and dilator muscles.

Authors:  H Ishikawa; Y Mitsui; T Yoshitomi; K Mashimo; S Aoki; K Mukuno; K Shimizu
Journal:  Jpn J Ophthalmol       Date:  2000 Mar-Apr       Impact factor: 2.447

2.  Sensitivity of embryonic rat dorsal root ganglia neurons to Clostridium botulinum neurotoxins.

Authors:  M J Welch; J R Purkiss; K A Foster
Journal:  Toxicon       Date:  2000-02       Impact factor: 3.033

3.  Disc degeneration of the lumbar spine in relation to overweight.

Authors:  M Liuke; S Solovieva; A Lamminen; K Luoma; P Leino-Arjas; R Luukkonen; H Riihimäki
Journal:  Int J Obes (Lond)       Date:  2005-08       Impact factor: 5.095

4.  Botulinum toxin injections for cervical dystonia.

Authors:  J Jankovic; K Schwartz
Journal:  Neurology       Date:  1990-02       Impact factor: 9.910

5.  Treatment of refractory, chronic low back pain with botulinum neurotoxin A: an open-label, pilot study.

Authors:  Bahman Jabbari; John Ney; Afsoun Sichani; William Monacci; Leslie Foster; Marc Difazio
Journal:  Pain Med       Date:  2006 May-Jun       Impact factor: 3.750

6.  Heritability of low back pain and the role of disc degeneration.

Authors:  Michele C Battié; Tapio Videman; Esko Levalahti; Kevin Gill; Jaakko Kaprio
Journal:  Pain       Date:  2007-03-01       Impact factor: 6.961

Review 7.  Evidence for antinociceptive activity of botulinum toxin type A in pain management.

Authors:  K Roger Aoki
Journal:  Headache       Date:  2003 Jul-Aug       Impact factor: 5.887

8.  Sympathetic activation of cat spinal neurons responsive to noxious stimulation of deep tissues in the low back.

Authors:  Richard G Gillette; Ronald C Kramis; William J Roberts
Journal:  Pain       Date:  1994-01       Impact factor: 6.961

9.  Subcutaneous administration of botulinum toxin A reduces formalin-induced pain.

Authors:  Minglei Cui; Sid Khanijou; John Rubino; Kei Roger Aoki
Journal:  Pain       Date:  2004-01       Impact factor: 6.961

10.  Predicting work status for patients in an occupational medicine setting who report back pain.

Authors:  M A Krousel-Wood; T W McCune; A Abdoh; R N Re
Journal:  Arch Fam Med       Date:  1994-04
View more
  6 in total

Review 1.  The efficacy of botulinum toxin type A in managing chronic musculoskeletal pain: a systematic review and meta analysis.

Authors:  Tony Zhang; Aleem Adatia; Wasifa Zarin; Misha Moitri; Abi Vijenthira; Rong Chu; Lehana Thabane; Walter Kean
Journal:  Inflammopharmacology       Date:  2010-11-13       Impact factor: 4.473

Review 2.  Clinical uses of botulinum neurotoxins: current indications, limitations and future developments.

Authors:  Sheng Chen
Journal:  Toxins (Basel)       Date:  2012-10-19       Impact factor: 4.546

3.  Investigational pharmacology for low back pain.

Authors:  Avinash K Bhandary; Gary P Chimes; Gerard A Malanga
Journal:  J Pain Res       Date:  2010-09-06       Impact factor: 3.133

Review 4.  Current status and future directions of botulinum neurotoxins for targeting pain processing.

Authors:  Sabine Pellett; Tony L Yaksh; Roshni Ramachandran
Journal:  Toxins (Basel)       Date:  2015-11-04       Impact factor: 4.546

5.  Efficacy of botulinum toxin type a for treating chronic low back pain.

Authors:  Seyed M Jazayeri; Alireza Ashraf; Habib M Fini; Hajar Karimian; Mohamadreza V Nasab
Journal:  Anesth Pain Med       Date:  2011-09-26

Review 6.  Interventional Therapies for Chronic Low Back Pain: A Focused Review (Efficacy and Outcomes).

Authors:  Vikram B Patel; Ronald Wasserman; Farnad Imani
Journal:  Anesth Pain Med       Date:  2015-08-22
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.